By Nono Hu, Senior Manager, Branding & Messaging, LSN
The cardiovascular sector presents unique challenges both to entrepreneurs and investors. The steep cost of Phase III trials and the strict regulatory standards applied to cardio drugs make investing in cardiovascular products a risky endeavour. Investors who dare to take on this field are rewarded with access to large markets, including a growing need for new cardio solutions in emerging economies. In addition to investors who take on cardio for the potential ROI, nonprofit funders see the potential for their dollars to make a significant global impact by backing early-stage companies.
For RESI @ TMCx, LSN has assembled a panel of veteran investors who are focused on meeting these challenges, Moderated by William Kohlbrenner, Consulting Scientist, Boston Innovation Capital & Scientist-in-Residence, Life Science Nation the audience will hear from:
- Ross Tonkens, Head of Science and Technology Accelerator, American Heart Association
- Jeffery Sheldon, General Partner & Managing Director, Citaretx
- Matt Crawford, Managing Director, PTV Healthcare Capital
- James Eadie, Principal, Sante Ventures
These investors will explain how they assess cardiovascular investment opportunities, what cardio entrepreneurs can do to differentiate themselves when seeking investment, and how to find investors who are interested in working with you in matters of the heart.
Next Phase Newsletter 
Leave a comment